Myriad Genetics, founded in 1991, is a genetic testing and precision medicine company focused on advancing health through molecular diagnostics and genomics. The company has conducted millions of genetic tests over its more than three decades of operation.
Its portfolio includes several diagnostic products across healthcare verticals. These include the myRisk Hereditary Cancer Test for assessing disease risk, the myChoice CDx companion diagnostic for ovarian cancer, and GeneSight, which aids in mental health medication selection. The company also offers prenatal screening tests.
Myriad's work spans oncology, mental health, prenatal care, and urology, operating within the medical diagnostics and precision medicine sectors.
